Jesse Pelletier (Ocean Ophthalmology Group, North Miami Beach, FL, USA) discusses the role of the antiseptic povidone-iodine (PVP-I), which is now routinely employed and will play a greater role in the future of healthcare, particularly in the COVID-19 era.
Questions:
1. Tell us about infection control in your office during this pandemic and where povidone-iodine (PVP-I) fits in?
2. What is the rationale behind PVP-I utilization in the nose and mouth?
3. Can you simply dilute “stock” PVP-I and use it?
4. Are these strategies broadly applicable to other specialties across medicine?
Disclosure: Jesse Pelletier is co-founder of Veloce BioPharma and Halodine, LLC.
touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and funded by Touch Medical Media
Published: 6 August 2020